ReviewFrontiers in oncology2017
Metformin: A Bridge between Diabetes and Prostate Cancer.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.British journal of cancer · 2018Trial
- Ligand-Based Pharmacophore Mapping and Virtual Screening for the Search of Biguanide-Like Molecules With Antidiabetic Potentials Targeting Liver Kinase B1.Biochemistry research international · 2026Article
- Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Metformin: A Dual-Role Player in Cancer Treatment and Prevention.International journal of molecular sciences · 2024Review
- Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action.Toxicology research · 2023Article
- Article
- A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer.Clinical Medicine Insights. Oncology · 2023Article
- Glucose metabolism controls human γδ T-cell-mediated tumor immunosurveillance in diabetes.Cellular & molecular immunology · 2022Article
- Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications.Biomolecules · 2022Review
- Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.Medical sciences (Basel, Switzerland) · 2022Review
- Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study.Cancers · 2021Article
- Metformin mitigates PLCε gene expression and modulates the Notch1/Hes and androgen receptor signaling pathways in castration-resistant prostate cancer xenograft models.Oncology letters · 2021Article
- Article
- The Influence of Anti-Diabetic Drugs on Prostate Cancer.Cancers · 2021Review
- Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?Frontiers in oncology · 2021Review
- Impact of diabetes on prognosis of gastric cancer patients performed with gastrectomy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Tumour metabolism and its unique properties in prostate adenocarcinoma.Nature reviews. Urology · 2020Review
- Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.Frontiers in oncology · 2020Article
- Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway.Frontiers in oncology · 2020Article
- Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer.Prostate international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) has become the most frequent type of cancer in men. Recent data suggest that diabetic patients taking metformin have a lower incidence of certain cancer, including PCa. Metformin is the most common drug used in type II diabetes mellitus; its use has been shown to lower the incidence of several cancers, although there are ambiguous data about the anticancer activity of metformin. A large number of studies examined the potential antineoplastic mechanism of metformin although it is not still completely understood. This review summarizes the literature concerning the effects of metformin on PCa cells, highlighting its numerous mechanisms of action through which it can act. We analyze the possible causes of the discordances regarding the impact of metformin on risk of PCa; we discuss the latest findings in this field, suggesting that metformin may have a future role in the management of PCa both as monotherapy and in combination with other drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.